Gilead and Merck announce Phase 2 data showing an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression at Week 24
Week 24 results support continued development as a potential long-acting oral combination treatment option in virologically suppressed people with HIV
Novel investigational combination regimen has the potential to be the first oral weekly HIV treatment, helping to address unmet needs
Read the full press release here.
SEE ALSO:
Source : Merck
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.